HUMA Share Price Performance
US$1.12
-2.67 (-70.49%)
62.7% undervalued intrinsic discount
US$3.00
Fair Value
Price US$1.12
AnalystLowTarget US$3.00
Fair ValueUS$3.00
Share Pricen/a
Humacyte, Inc. Stock Price
- 1 Narratives written by author
- 1 Comments on narratives written by author
- 71 Fair Values set on narratives written by author
HUMA Community Narratives
AN
Fair Value US$3 62.7% undervalued intrinsic discount
Dialysis Access And Vascular Trauma Challenges Will Eventually Support A Stronger Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Dialysis Access And Vascular Trauma Challenges Will Eventually Support A Stronger Long Term Outlook
Catalysts About Humacyte Humacyte develops off the shelf bioengineered human vessels to address complex vascular and surgical needs across trauma, dialysis access and cardiovascular indications. What are the underlying business or industry changes driving this perspective?Read more
22
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$3
62.7% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
275.94% p.a.
Profit Margin
16.03%
Future PE
63.75x
Price in 2028
US$2.59
Trending Discussion
Recently Updated Narratives
AN
Dialysis Access And Vascular Trauma Challenges Will Eventually Support A Stronger Long Term Outlook
Fair Value: US$3 62.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Humacyte, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.20
- -4,697.77%
- -2,353.21%
- -445.1%
About HUMA
- Founded
- 2004
- Employees
- 219
- CEO
- WebsiteView website
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
